Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel plus O6-benzylguanine in recurrent glioblastoma multiforme
NCT00362921Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2004
- Primary completion
- Aug 2007
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 6-benzylguanine in glioblastoma multiforme (GBM), sponsored by Duke University. Primary endpoint: 6-month overall survival. Started Apr 2004; status: completed.
02
Drugs
6-benzylguanine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00362921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362921.